Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients

This study has been completed.
Information provided by (Responsible Party):
VA Office of Research and Development Identifier:
First received: April 27, 2010
Last updated: February 13, 2015
Last verified: February 2015

The incidence and prevalence of IPF increase exponentially with age, and IPF occurs more often in older males. Cigarette smoking and environmental dust exposures are known risk factors for developing IPF. For example, the recently deployed military population, as it ages, is at especially increased risk of IPF. No effective therapies exist, although lung transplantation is used to extend survival of selected patients.

Defining specific therapy to improve exercise tolerance and dyspnea in IPF patients is thus an urgent priority of veteran-oriented research programs.

Condition Intervention
Idiopathic Pulmonary Fibrosis
Behavioral: pulmonary rehabilitation

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rehabilitation of IPF Patients: Effects of Exercise and Oxidant Stress

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • 6 Minute Walk Distance [ Time Frame: The 6-MWD will be measured at 0 and 3 months. ]
    Change in 6 Minute Walk Distance from Baseline to 3 Months

Secondary Outcome Measures:
  • Systemic Markers of Oxidant Stress [ Time Frame: Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months. ]
    Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.

  • Maximum Oxygen Uptake [ Time Frame: Maximum O2 uptake will be measured at 0 and 3 months. ]
    Change in 6 peak O2 uptake from Baseline to 3 Months

Enrollment: 25
Study Start Date: October 2010
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
enroll in pulmonary rehabilitation program
Behavioral: pulmonary rehabilitation
structured exercise program
No Intervention: Arm 2
no structured exercise

  Show Detailed Description


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical presentation consistent with IPF with onset between three months and 48 months prior to screening.
  • Diagnosis made by high-resolution computed tomographic scan showing highly probable IPF.
  • Absence of severe pulmonary hypertension (i.e., PAsys must be less than 55 mm Hg, based on echocardiography) and absence of decompensated right heart failure (NYHA class I or II acceptable).
  • Age 40 through 80, inclusive.
  • Abnormal pulmonary function tests (FVC 40-90% predicted or DLCO 30-90% predicted or impaired gas exchange with rest or exercise).
  • Six-minute walk distance 150 m and 500 m.
  • Worsening as demonstrated by any one of the following within the past year: > 10% decrease in percent predicted forced vital capacity or worsening dyspnea at rest or upon exertion, based on history.
  • Ability to understand and sign a written informed consent form and comply with the requirements of the study.
  • Absence of clinical features suggesting infection, neoplasm, sarcoidosis or collagen-vascular disease.

Exclusion Criteria:

  • Echocardiographic evidence of severe pulmonary hypertension (PAsys>55 mm Hg, based on echocardiography or TR velocity 3.2 m/sec).
  • Severe heart failure (NYHA class III or IV or LVEF < 45%).
  • Six-minute walk distance < 150 m or > 500 m.
  • FEV1/FVC ratio < 0.7 at screening (post-bronchodilator).
  • Residual volume > 100% predicted.
  • Any condition other than IPF likely to result in the death of the participant within the next two years.
  • History of unstable or deteriorating cardiac or neurologic disease.
  • Pregnancy or lactation. Patients who are: (a) pregnant or (b) breast feeding are excluded from the study.
  • Current treatment with corticosteroids (either oral or inhaled), Cytoxan, azathioprine, colchicine, pirfenidone, anti-tumor necrosis factor therapy or endothelin receptor blockers. Prior treatment is permitted, but at least four weeks of treatment washout prior to inclusion in this study are required.
  • Investigational therapy for any indication within 28 days prior to enrollment.
  • Degenerative arthritis, cerebrovascular accident or other limitation to mobility preventing completion of the 6-minute walk test.
  • Oxygen saturation on room air <80% at rest.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01118221

United States, Florida
VA Medical Center, Miami
Miami, Florida, United States, 33125
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: Robert M Jackson, MD VA Medical Center, Miami
  More Information

Responsible Party: VA Office of Research and Development Identifier: NCT01118221     History of Changes
Other Study ID Numbers: O7467-R
Study First Received: April 27, 2010
Results First Received: November 19, 2014
Last Updated: February 13, 2015

Keywords provided by VA Office of Research and Development:
oxidant stress

Additional relevant MeSH terms:
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial processed this record on April 28, 2017